Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages  by Visentin, Barbara et al.
A R T I C L EValidation of an anti-sphingosine-1-phosphate antibody
as a potential therapeutic in reducing growth, invasion,
and angiogenesis in multiple tumor lineages
Barbara Visentin,1,5 John A. Vekich,1,5 Bradley J. Sibbald,1 Amy L. Cavalli,2 Kelli M. Moreno,2
Rosalia G. Matteo,2 William A. Garland,2 Yiling Lu,3,5 Shuangxing Yu,3,5 Hassan S. Hall,3
Vikas Kundra,4 Gordon B. Mills,3 and Roger A. Sabbadini1,2,*
1 Department of Biology, San Diego State University, San Diego, California 92182
2 Lpath, Inc., San Diego, California 92121
3 Departments of Molecular Therapeutics and Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas 77054
4 Departments of Radiology and Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston,
Texas 77054
5 These authors contributed equally to this work.
*Correspondence: rsabba@sunstroke.sdsu.edu
Summary
S1P has been proposed to contribute to cancer progression by regulating tumor proliferation, invasion, and angiogenesis.
We developed a biospecific monoclonal antibody to S1P to investigate its role in tumorigenesis. The anti-S1PmAb substan-
tially reduced tumor progression and in somecases eliminatedmeasurable tumors inmurine xenograft and allograftmodels.
Tumor growth inhibition was attributed to antiangiogenic and antitumorigenic effects of the antibody. The anti-S1P mAb
blocked EC migration and resulting capillary formation, inhibited blood vessel formation induced by VEGF and bFGF, and
arrested tumor-associated angiogenesis. The anti-S1PmAb also neutralized S1P-induced proliferation, release of proangio-
genic cytokines, and the ability of S1P to protect tumor cells from apoptosis in several tumor cell lines, validating S1P as
a target for therapy.Introduction
The identification of signaling components that promote tumor
growth represents an important step toward discovering new
therapies to reduce the morbidity and mortality of cancer. In
this regard, the bioactive lysolipid signaling molecule sphingo-
sine-1-phosphate (S1P) is a little-explored target for antitumor
treatment. Evidence suggests that S1P may play a major regu-
latory role in tumor biology by having direct effects both on tu-
mor-associated angiogenesis and on the tumor cells them-
selves (Ogretmen and Hannun, 2004).
S1P is a mediator of tumor cell proliferation and protects tu-
mor cells from apoptosis through the activation of survival path-
ways (Maceyka et al., 2002; Spiegel and Milstien, 2003; Radeff-
Huang et al., 2004). The balance between S1P and ceramide/
sphingosine (CER/SPH) levels, the upstream precursors of
S1P, is believed to provide a rheostat mechanism that deter-
mines whether a cell proliferates or undergoes apoptosisCANCER CELL 9, 225–238, MARCH 2006 ª2006 ELSEVIER INC. DOI 10(Kwon et al., 2001; Maceyka et al., 2002). The key regulatory en-
zyme of the rheostat mechanism is sphingosine kinase (SPHK),
whose role is to convert the death-promoting sphingolipids
(CER/SPH) into the growth-promoting S1P (Bektas et al.,
2005). Indeed, SPHK1 transfectants produced tumors when in-
jected into mice (Xia et al., 2000). Furthermore, cells overex-
pressing SPHK escape contact inhibition, a property commonly
exhibited by transformed cells. The reported loss of contact in-
hibition is consistent with reports suggesting that S1P produc-
tion correlates with the metastatic potential of selected human
cancer cell lines (Takuwa, 2002; Yamaguchi et al., 2003). Addi-
tionally, high levels of SPHK1 expression in certain tumor tissues
correlate with lower patient survival, thus suggesting a connec-
tion between SPHK1 and the aggressiveness of these tumors
(Van Brocklyn et al., 2005).
S1P contributes to angiogenesis (Allende and Proia, 2002;
Argraves et al., 2004) by stimulating DNA synthesis, chemotac-
ticmotility, and capillary tube formation of endothelial cells (ECs)S I G N I F I C A N C E
The data suggest that S1P is required for the neovascularizing activity of VEGF and bFGF as well as angiogenesis induced by multiple
cytokines. Thus, neutralizing S1P with anti-S1P monoclonal antibodies has the potential to block neovascularization in multiple tumor
lineages and is less likely to be bypassed by production of multiple factors than are other approaches to targeting tumor vessels. Fur-
ther, the data suggest that S1P is required for proliferation and invasion of multiple tumor lineages. Thus, the anti-S1PmAbwarrants clin-
ical evaluation to determine its efficacy in reducing cancer progression by neutralizing the proliferative, invasive, and angiogenic ef-
fects of S1P. Thus, the anti-S1P mAb may represent a noncancer type-specific therapy for use in humans..1016/j.ccr.2006.02.023 225
A R T I C L Eand bone marrow-derived EC precursors, processes that con-
tribute to early blood vessel formation (Lee et al., 1999). The
capillary tube formation induced by S1P is comparable to that
of the well-known proangiogenic mediators basic fibroblastic
growth factor (bFGF) and vascular endothelial growth factor
(VEGF) (Lee et al., 1999). Furthermore, S1P elicits synergistic
effects with these growth factors to promote development of
vascular networks in vivo (Wang et al., 1999). Recently, cross-
talk between S1P and other proangiogenic growth factors
such as VEGF, EGF, PDGF, bFGF, and IL-8 has been reported
(Schwartz et al., 2001; Spiegel and Milstien, 2003). Importantly,
bevacizumab (Avastin), a monoclonal antibody that selectively
absorbs VEGF from the extracellular fluid (Ferrara, 2004), dem-
onstrated efficacy in limiting the progression of three major
types of human cancer. The success of Avastin has stimulated
an exploration for similar and more efficacious targets to block
tumor-associated angiogenesis. Since S1P is required for the
optimal activity ofmultiple proangiogenic factors, S1P is a prom-
ising target for novel therapeutic approaches.
These findings indicate that lowering the interstitial concen-
tration of S1P in tumors could provide a less favorable growth
environment for cancer cells by decreasing angiogenesis, while
decreasing proliferation and metastatic potential and increasing
sensitivity to apoptosis. For this reason, we have produced
a monoclonal antibody against S1P (anti-S1P mAb) that is spe-
cific to S1P and can bind and neutralize extracellular S1P at its
physiologically relevant concentrations. In addition to providing
a sensitive probe of the in vivo function of S1P, we hypothesize
that this antibody could prove useful as a therapeutic molecular
sponge to selectively absorb S1P, thus lowering effective extra-
cellular concentrations of this tumor growth factor.
In this study, we demonstrate that neutralization of S1P re-
sults in the reduction of tumor growth through multiple mecha-
nisms including reduced tumor proliferation, cell survival, and
metastatic potential concurrently with reduced vessel formation
and function. The efficacy of the molecular absorption of S1P in
these models suggests that treatment with a humanized version
of the murine anti-S1P antibody may provide an innovative and
useful approach to cancer therapeutics.
Results
Characteristics of the anti-S1P mAb
Competitive ELISA was used to determine the specificity and
sensitivity of the anti-S1P mAb. Figure 1A shows that the anti-
S1P mAb was capable of recognizing S1P over the range of
S1P concentrations used in the cell-based experiments de-
scribed below. The anti-S1P mAb was unable to recognize the
structurally related bioactive lysolipid lysophosphatidic acid
(LPA) or the bioactive precursor to S1P, SPH. Other lysolipids
and phospholipids including CER, ceramide-1-phosphate
(C1P), and phosphatidyl ethanolamine (PE) were tested without
observing appreciable antibody crossreactivity with the excep-
tion of the fully saturated form of S1P,DH-S1P, and modest
crossreactivity with sphingosylphosphoryl choline (SPC). Neu-
tralizing SPC as well as S1P with the antibody could be advan-
tageous because SPC itself is tumorigenic (Beil et al., 2003).
However, extracellular levels of SPC are low, likely due to the
presence of autotoxin which has recently been shown to convert
SPC to S1P (Clair et al., 2003).226A study utilizing BIAcore demonstrated that the anti-S1PmAb
has an affinity for S1P of 99.76 14.4 pM (SD; n = 3). This affinity
is over 100-fold higher than the reported affinity of S1P recep-
tors for S1P and much higher than the nonspecific binding sites
on serum proteins (Richieri et al., 1993).
To determine the dosing for subsequent in vivo experiments,
the in vivo t1/2 of the anti-S1P mAb was determined. A compet-
itive ELISA was used to determine the pharmacokinetics of the
anti-S1P mAb in blood. Figure 1B shows the time course of the
anti-S1P mAb elimination with the dosing of 25 mg/kg. Using
a standard two compartment model calculation in WinNonlin, a
t1/2 (elimination) of 20–26 hr was determined. This t1/2 is con-
sistent with the pharmacokinetic profiles of other therapeutic
antibodies (Ignoffo, 2004). A simulation of dosing of 25 mg/kg
anti-S1P mAb every 2 days demonstrated the concentrations
of antibody in the mouse that did not significantly accumulate
over time (Figure S1 in the Supplemental Data available with
this article online). Intraperitoneal injection of a bolus dose of
the anti-S1P mAb revealed that over 95% of the antibody ap-
peared in the bloodstream after 20 min, suggesting that mice
could effectively be dosed either intraperitoneally (i.p.) or intra-
venously (i.v.). We have calculated that the molar ratio of anti-
S1P mAb to plasma S1P isw3:1 at the 25 mg/kg dose injected
into a 20 g mouse and assuming a plasma volume of 1.4 ml with
a S1P concentration (total) of 2.45 mM.
We conducted a 7 day toxicology study to determine how the
antibody was tolerated. Mice were administered (by tail vein in-
jection) 1, 3, 10, 30, or 50 mg/kg of the anti-S1P mAb or vehicle
for 7 consecutive days. Figure 1C demonstrates a few selected
parameters for the 50 mg/kg and saline dosing. All biochemical
and CBC panel analyses were within normal ranges. Histopath-
ological examination revealed no lesions or other pathological
changes in the liver, kidney, heart, lungs, skeletal muscle, or
spleen of mice in any dosing group. Mice in all treatment groups
consumed food and water and socialized similarly to control an-
imals. In one of the xenograft studies described below, mice
were administered i.p. 25 mg/kg of the anti-S1P mAb every
other day for up to 6 weeks. Even though this was not a bona
fide toxicology study, mice in this study exhibited no prominent
abnormalities of the major organs upon sacrifice.
Anti-S1P antibodies slow tumor progression
in multiple murine models
The ability of the anti-S1PmAb to inhibit cancer progressionwas
tested in three orthotopic models using the breast carcinoma
cells MDA MB-231 and MDA MB-468, and the ovarian cancer
cell line SKOV3. The anti-S1PmAbwas also tested in a subcuta-
neous xenograft model using lung adenocarcinoma A549 cells.
Figures 2A and 2B show the effects of the systemic anti-S1P
mAb treatment on MDAMB-231 multidrug-resistant breast car-
cinomas orthotopically placed in the mouse mammary fat pads
(Figure 2A). The ability of the anti-S1P mAb to reduce tumor vol-
umes was most apparent after the tumors reached approxi-
mately 400 mm3, where tumors of the anti-S1P mAb-treated
animals nearly stopped growing. At the end of the study, MDA
MB-231 tumor volumes and weights were reduced by 62% and
40% (Figure 2A; *p < 0.001), respectively. The anti-S1P mAb was
as effective as weekly paclitaxel in decreasing tumor volume
in these mice (data not shown).
In a similar orthotopic breast cancer study (Figure S2), MDA
MB-468 tumor volumes were reduced by 40% with respect toCANCER CELL MARCH 2006
A R T I C L EFigure 1. Characteristics of the anti-S1P mAb
A:Competitive ELISA demonstrating the ability of
the anti-S1P mAb to recognize S1P but not LPA,
SPH, or other related lipids.
B: Mice were treated with a bolus dose of 25 mg/
kg of the anti-S1P mAb. The elimination t1/2 of the
antibody, as determined by the concentration
of mAb in the serum at designated time points
using a competitive ELISA, was calculated to
be 22–26 hr.
C: Represented toxicological data from mice
(four in each group) dosed i.v. every day with
50 mg/kg anti-S1P mAb. Values are means 6
SD and demonstrate the lack of adverse effects
elicited by the anti-S1P mAb.saline controls (*p < 0.05). These data confirm the efficacy of the
anti-S1PmAb against two humanmultidrug-resistant orthotopic
breast cancer models.
We next evaluated the ability of the anti-S1P mAb to alter the
progressionof larger andverywell-established tumors (Figure 2).
In the orthotopic MDA MA-231 model, tumors were allowed to
establish until they reached an approximate volume of 700–
800mm3 (10-fold larger than those used in Figure 2A) before an-
tibody (specific or nonspecific) treatments were commenced.CANCER CELL MARCH 2006As shown, the anti-S1P mAb-treated animals exhibited signifi-
cantly reduced tumor volumes. By the 14th day, the final tumor
volumes from the anti-S1P mAb-treated mice were reduced by
over 58% (*p < 0.001) by comparison to tumors from control
mice. After 2 weeks, the treatment was ceased in half of the
mice receiving the anti-S1P mAb, and the progression of the tu-
mors was evaluated for 12 additional days. After a delay of 3
days, tumors from the mice no longer receiving the anti-S1P
mAb once again started to grow compared to tumors from227
A R T I C L EFigure 2. The anti-S1P mAb reduces tumor progression in multiple models
Orthotopically placed MDA MB-231 (A and B), SKOV3 (C–E), and s.c. A549 (F) tumors were established to volumes of 75–100 mm3 (A, C, and E) or 700–800 mm3
(B) in nude mice. Treatments consisted of 25 mg/kg of the anti-S1P mAb, 25 mg/kg of nonspecific mAb, saline administrated every 3 days i.p., and 10 mg/kg of
Taxol administrated once a week. In all tested xenografts, the anti-S1P mAb reduced significantly final tumor volumes (mm3) by 62% (A), by 58% (B), and by 42%228 CANCER CELL MARCH 2006
A R T I C L Eanimals maintained on antibody treatment. This lag suggests
that the t1/2 of 26 hr (see Figure 1B) was likely an underestimate
of the physiological half-life of the effective antibody dose.
Figures 2C–2E demonstrates that the anti-S1P mAb was effi-
cacious in inhibiting the progression and, in some cases, elimi-
nating orthotopic SKOV3 tumors in nude mice. MRI analysis
revealed that all saline control mice contained large tumors
throughout the peritoneal cavity and that these mice had accu-
mulated observable amounts of ascites. Conversely, in two out
of the five animals treated with the anti-S1P mAb, no tumors or
ascites were detected byMRI analysis or upon postmortem dis-
section of the peritoneal cavity. Three out of the five animals
treated with the anti-S1P mAb had detectable tumors; signifi-
cantly, these tumors were 68% smaller (750 mg versus 2300
mg) than tumors from the saline-treated animals (*p < 0.05).
These results compare favorably to a very similar study showing
thatmouse anti-human VEGFmAb (A.4.6.1) produced a 47% re-
duction in the size of SKOV3 tumors by MRI (Gossmann et al.,
2000). The SKOV3 intraperitoneal model was also assessed
for CD31 and H&E staining (Figure 2E). Anti-CD31-labeled sec-
tions (upper panel) showed a marked decrease in EC staining of
tumor vessels in the anti-S1P mAb-treated mice (representative
mouse of five analyzed). Further, H&E staining (lower panel) re-
vealed evidence of increased fibrosis in anti-S1P mAb-treated
mice.
Figure 2F shows data using xenografted A549 lung carcinoma
cells where the A549 tumor volumes were significantly (*p <
0.05) reduced in the antibody-treated animals when compared
to animals treated with saline as a control (58% reduction) or an-
imals treated with the nonspecific antibody (42% reduction).
The ability of the anti-S1P mAb to retard tumor growth was
equivalent to mice treated with Taxol as a positive control. The
excised tumors were evaluated for histopathological features
in order to determine the full extent of the anti-S1P effects on
the viability of remaining tumor cells. H&E-stained sections of
the A549 tumors revealed that the tumors from the anti-S1P
mAb-treated animals exhibited larger necrotic cores as well as
extensive fibrosis (Figure 2G, top panel). Only the tumor periph-
eries showed appreciable numbers of viable tumor cells. Histo-
logical examination indicated that the measurements of gross
tumor volumes seen in Figure 2F may have underestimated
the actual antitumorigenic effects of the anti-S1P mAb, consid-
ering that gross tumor volumes also take into account the vol-
ume occupied by dead cells and fibrotic tissue (as also seen
in the SKOV3 tumors; Figure 2E). In both control and anti-S1P
mAb-treated animals, the vascularization within each tumor
was largely confined to the viable regions of the tumor at the pe-
riphery rather than in the necrotic core. The extent of tumor-
associated angiogenesis was largely mitigated by the anti-S1P
mAb treatment, as evidenced by the overall lack of robust mi-
crocapillary staining with the isolectin (Figure 2G, bottom panel).
In parallel experiments, EC staining with anti-CD31 revealed
substantial (3.3-fold) and significant (#p < 0.05) reductions inCANCER CELL MARCH 2006EC presence in the A549 tumors of anti-S1P mAb-treated
animals (Figure 2G), similar to the CD31 staining of the SKOV3
tumors (Figure 2E).
Taken together, these in vivo xenograft models demonstrate
that the observed antitumor effects of the anti-S1P mAb were
not cancer type specific. Furthermore, the efficacy of the anti-
S1P mAb in slowing tumor progression was not dependent on
the size of the tumors at the initiation of treatment. Thus, S1P ap-
pears to play amajor role in tumorigenesis and vascularization in
multiple tumor lineages.
The anti-S1P mAb inhibits the release of proangiogenic
growth factors in vitro and in vivo
Figure 3A demonstrates that 1 mM S1P induced substantial (2-
to 4-fold) increases in IL-6, IL-8, and VEGF release from MDA
MB-231 cells in vitro. Figure 3A also demonstrates that treat-
ment of cells with S1P after preincubation with the anti-S1P
mAb caused a reduction in the extent of cytokine release to
basal levels or less. Secreted VEGF levels were nearly undetect-
able after antibody treatment, suggesting a potential autocrine
stimulatory loop in MDA MB-231. S1P also elicited significant
release of IL-8 into the cell-conditioned media from cultured
SKOV3 and OVCAR3 cells, and addition of the anti-S1PmAb re-
duced IL-8 release from all tumor types in a concentration-
dependent manner (Figure S3).
Figure 3B demonstrates that serum from MDA MB-231 and
SKOV3 xenografted animals displayed substantial levels of the
three human cytokines, IL-6, IL-8, and VEGF. Consistent with
the in vitro observations of Figure 3A, animals treated with the
anti-S1P mAb had significantly reduced (2- to 4-fold) levels of
all circulating proangiogenic cytokines tested. Both the in vitro
and in vivo data demonstrate that one of the effects of S1P on
angiogenesis may be its ability to induce the release of a variety
of other proangiogenic compounds.
The anti-S1P mAb blocks the function of proangiogenic
growth factors in vivo
Figure 4 compares the proangiogenic activities of S1P, bFGF, or
VEGF in vivo when added to theMatrigel plugs. Figure 4A shows
that all three growth factors induced substantial evidence
of vascularization compared to control animals whose plugs
were lacking the growth factors. Notably, S1P was as potent
as VEGF and bFGF used at their optimum concentrations in
the Matrigel plug assay.
Endogenous S1P has been shown to act synergistically with
other growth factors such as bFGF and VEGF in stimulating
angiogenesis (Licht et al., 2003). We hypothesized that endoge-
nous S1P from the blood and surrounding tissue may represent
an additional proangiogenic factor to supplement plugs contain-
ing either VEGF or bFGF. To evaluate these hypotheses, mice
implanted with plugs containing VEGF or bFGF received injec-
tions of the anti-S1P mAb. Figure 4B shows representative ex-
amples of plugs where the neovascularization effects of eitherand 58% (F). Inset figures represent final tumor weights (mg). C shows MRI images of animals bearing SKOV3 tumors, demonstrating substantial absence of
tumors and lack of ascites production in animals treated with the anti-S1P mAb. SKOV3 tumor weights were reduced 68% (D). For A and C n = 5 and 5, for
B n = 10 and 15, and for F n = 8 and 9 mice treated with control (saline vehicle or nonspecific mAb, as indicated) and anti-S1P mAb, respectively. CD31
and H&E staining of ECs in the SKOV3 tumors (E) show that the anti-S1P mAb reduced tumor-associated angiogenesis and increased fibrosis. H&E staining
of A549 tumors (G) also demonstrates that the anti-S1P mAb increased central necrosis (asterisk). In A549 tumors, isolectin staining of developed microcapil-
laries (G) and CD31 staining of ECs (H) both show that the anti-S1P mAb reduced tumor-associated angiogenesis (white arrows indicate tumor margins). *p <
0.01 for the anti-S1P mAb versus saline- or nonspecific mAb-treated mice and #p < 0.05 for the anti-S1P mAb versus the stop treatment. All data are repre-
sented as the mean 6 SEM.229
A R T I C L EVEGF or bFGF were mitigated by systemic treatment with the
anti-S1P mAb. Quantification of data from all mice in the study
(Figure 4C) shows that the VEGF- or bFGF-containing plugs
from mice treated with 25 mg/kg of the anti-S1P mAb exhibited
substantial reductions (82% and 89%, respectively) in blood
vessel formation compared to VEGF- or bFGF-containing plugs
from mice that did not receive the anti-S1P mAb. In the bFGF-
containing plugs, the reduction in vascularization were dose de-
pendent, as 1 mg/kg or 25 mg/kg of anti-S1P mAb reduced the
bFGF-dependent vascularization by 32% and 89%, respec-
tively. The ability of the anti-S1P mAb to block these effects
suggests that endogenous S1P present in plasma and tissues
or produced in the Matrigel plug has the ability to enhance mi-
crovascularization induced by other key proangiogenic growth
factors.
Figure 3. The anti-S1P mAb inhibits the release of proangiogenic growth fac-
tors from tumor cells in vitro and in vivo
A: Representative data demonstrating that S1P increases the release of IL-6,
IL-8, and VEGF from MDA MB-231 tumor cells into the cell-conditioned me-
dia. The release is completely neutralized by incubation with 1 mg/ml of
the anti-S1P mAb, in vitro.
B: Serum from MDA MB-231 and SKOV3 xenografted animals reveals
the ability of the anti-S1P to reduce plasma levels of IL-6, IL-8, and VEGF.
*p < 0.05 for the anti-S1P mAb versus saline- or nonspecific mAb-treated mice.
All data are represented as the mean 6 SEM.230The anti-S1P mAb inhibits tumor vascularization
by directly influencing ECs in vitro and in vivo
Enhanced EC survival is a critical component of angiogenesis.
The ability of ECs to survive depends upon circumventing cell
death induced by hypoxia as well as chemotherapy. Accord-
ingly, the ability of S1P to protect human umbilical vein endothe-
lial cells (HUVECs) from apoptosis induced by two clinically rel-
evant chemotherapeutic agents, doxorubicin and paclitaxel,
was investigated. Figure 5A shows that HUVECs were sensitive
to doxorubicin (4.4-fold increase in caspase activity after 24 hr of
treatment) and, to a lesser extent, paclitaxel (2.2-fold increase).
S1P induced a statistically significant reduction of caspase-3
activation in HUVECs exposed to both of the chemotherapeutic
drugs (31% and 33%, respectively, for doxorubicin and pacli-
taxel). As expected, the addition of the anti-S1P mAb com-
pletely abolished the protective, antiapoptotic effects of S1P.
Thus, S1P has the ability to protect HUVECs from the toxicity
of chemotherapy agents.
The ability of ECs to migrate to the site of a tumor is also an
important part of tumor-associated angiogenesis. Figure 5B
shows a substantial HUVECmigration response following expo-
sure to S1P. The addition of 1 mg/ml anti-S1P mAb to the media
blocked S1P-induced migration of HUVECs by 70%.
In vitro studies have shown that S1P not only stimulates
HUVEC chemotactic motility but also induces HUVEC differen-
tiation intomulticellular structures suggestive of early blood ves-
sel formation even in the absence of growth factors (Lee et al.,
1999). Figure 5C shows that serum-deprived HUVECs placed
on growth factor-reduced (GFR) Matrigel failed to form capil-
lary-like structures in the absence of S1P. Upon the addition
of 1 mMS1P, HUVECs formed elongated tube-like structures af-
ter only 6 hr. The addition of the anti-S1P mAb substantially
blocked the formation of the typical capillary-like structures for
the duration of the experiment.
A critical stem in tumor vascularization is the infiltration and
proliferation of ECs into the tumor as a consequence of the
tumor-associated release of angiogenic factors. Accordingly,
the ability of S1P to promote the infiltration of ECs into plugs
was evaluated in vivo using the Matrigel plug assay (Figure 5D).
Animals that were injected with Matrigel containing 5 mM S1P
showed a substantial (>6-fold) and significant (*p < 0.001) in-
crease in the density of ECs compared to those injected with
Matrigel lacking S1P. The administration of anti-S1P mAb com-
pletely neutralized the ability of S1P-saturated plugs to promote
cell infiltration, as no significant differences were found between
antibody-treated animals and controls not treated with S1P.
Considering that the anti-S1P mAb may neutralize S1P’s abil-
ity to induce the release of proangiogenic growth factors (Fig-
ure 3) and to promote de novo blood vessel formation in vivo
(see Figures 2E, 2G, and 2H), one may speculate that tumor
growth may depend on S1P-mediated angiogenesis, which
could account for the ability of the anti-S1PmAb to retard tumor
growth (Figures 2A–2D and 2F). The ability of the anti-S1P mAb
to block angiogenesis was evaluated in the murine melanoma
(B16-F10) allograft model. B16-F10 cells are known to be unre-
sponsive to S1P in terms of proliferation, protection from doxo-
rubicin-induced apoptosis, and promotion of cell migration (see
below) (Arikawa et al., 2003; Yamaguchi et al., 2003). Therefore,
if one were to observe an effect of the anti-S1PmAb on B16-F10
tumor growth in vivo, one could argue that this would be due to
an antiangiogenic effect from the antibody rather than a directCANCER CELL MARCH 2006
A R T I C L EFigure 4. The anti-S1P mAb inhibits the proangio-
genic effects of bFGF and VEGF in vivo
GFR Matrigel containing bFGF, VEGF, S1P, or
saline was implanted into mice. Selected
animals received 1 or 25 mg/kg of the anti-S1P
mAb or saline every 48 hr, starting a day prior to
matrix implantation. After 10 days, the plugs
were harvested and analyzed for microvascular
density by FITC-isolectin staining functional ves-
sels. In A are representative images (scale 80
mm) showing the neovascularization effects of
S1P (5 mM) compared to optimum concentra-
tions of VEGF (10 mg/ml) and bFGF (500 ng/ml)
all mixed with the GFR Matrigel prior to implanta-
tion. B shows representative images (scale
200 mm) of plugs premixed with either VEGF
(10 mg/ml) or bFGF (1 mg/ml) prior to implantation
in mice that were treated systemically with the
anti-S1P mAb. C is a quantification of data from
all treatment groups (n = 3–4 per group). Animals
bearing VEGF and bFGF plugs and in treatment
with 25 mg/kg of the anti-S1P mAb showed 82%
and 89% reduction in tumor vasculature com-
pared to control groups. p < 0.001 for *VEGF or
bFGF versus saline (Matrigel alone) and #VEGF
or bFGF versus VEGF or bFGF plus anti-S1P mAb.
All data are represented as the mean 6 SEM.effect of the antibody on tumor cells. Accordingly, animals were
implanted with B16-F10 melanoma cells and treated with the
anti-S1P mAb. Figure 5E shows that animals treated with anti-CANCER CELL MARCH 2006S1P mAb exhibited on average a 57% reduction in tumor vol-
ume (and a 53% reduction in tumor weight) compared to control
animals treated with saline or the nonspecific antibody. To231
A R T I C L EFigure 5. The anti-S1P mAb inhibits vascularization in vitro and in vivo
The anti-S1P mAb (1 mg/ml) reduced HUVEC survival against standard chemotherapeutics, doxorubicin (850 nM; Dox) or Taxol (50 nM; Tax) (A), migration (B),
and the formation of capillary-like structures (C) when exposed to 1 mM S1P. Data are expressed as fold increases of caspase-3 activation or migrating cells232 CANCER CELL MARCH 2006
A R T I C L Eassess tumor angiogenesis after treatment with the anti-S1P
mAb, we examined excised B16-F10 tumors for isolectin and
CD31 staining. As Figure 5F demonstrates, treatment with the
anti-S1P mAb resulted in a substantial (61%) and significant
(*p = 0.023) reduction in tumor microcapillary density after stain-
ing with the isolectin. Similarly, Figure 5G shows that the anti-
S1P mAb significantly (6p < 0.05) reduces the presence of EC
density as quantified by anti-CD31 staining.
Anti-S1P mAb’s direct effects on tumor cells
A variety of human tumor cell lines as well as the mouse-derived
B16-F10 cells were tested in vitro for the ability of S1P to stim-
ulate invasion, proliferation, and protection from cytotoxic
agents. The in vitro Matrigel cell invasion assay was employed
to evaluate cellular invasion as an indicator of metastatic poten-
tial for several cell lines (A549, HT-29, MCF-7, and B16-F10). As
shown in Figure 6A, treatment with S1P induced a substantial
(6- to 7-fold) increase in invasion through the Matrigel matrix in
multiple tumor cell lines when compared to nontreated control
cells. Only the B16-F10 cells were not stimulated by S1P in
this assay. Addition of anti-S1P mAb reduced the chemotactic
migration of S1P-responsive cells into the Matrigel matrix to
control levels regardless of the concentration of S1P used.
The dose dependence of S1P-induced invasion in the Matrigel
matrix was evaluated for the A549 cell line where 1 mg/ml anti-
S1P mAb neutralized all of the S1P concentrations tested (Fig-
ure S4). These results suggest that this concentration of anti-
body was sufficient to absorb up to 1 mM S1P as a result of
the higher affinity of the antibody for S1P compared to S1P re-
ceptors on the A549 cell surfaces.
The ability of the anti-S1P mAb to neutralize S1P-induced
stimulation of cellular proliferation in multiple cell lines was
also evaluated. Figure 6B demonstrates the ability of S1P to in-
crease [3H]-thymidine incorporation in cells treated with 100 nM
S1Pwhen compared to nontreated control cells. The increase in
DNA synthesis produced by S1P was completely mitigated by
the addition of 1 mg/ml of the anti-S1P mAb.
The ability of the anti-S1P mAb to alter tumor cell survival un-
der the stress of chemotherapeutic agents was accessed by ex-
posing multiple tumor cell lines to 1 mM doxorubicin. Tumor cell
death was assessed by the activation of the apoptotic execu-
tioner caspase-3 or H/PI (Figure 6C). As shown, S1P was able
to decrease doxorubicin-induced caspase-3 activation and/or
cell death to control, nontreated levels in almost all of cell types
tested. With the exception of the B16-F10 cells, caspase-3 ac-
tivation was increased by the anti-S1P mAb in the presence of
S1P, suggesting that the protective antiapoptotic effect of S1P
was eliminated by selective absorption of the lysolipid by the
antibody. The ability of the anti-S1P mAb to neutralize the
antiapoptotic effects of S1P depended on the dose testedCANCER CELL MARCH 2006Figure 6. The anti-S1P mAb inhibits many of the protumorigenic processes
The anti-S1P mAb (1 mg/ml) mitigated S1P-induced migration (A), tumor cell
proliferation (B), and cell survival against doxorubicin (Dox) (C) in all the tu-
mor cell lines tested with the exception of B16-F10 cells. Data are expressed
as fold increases of migrating cells, proliferation, or caspase-3 activation
with respect to the control cells, in at least three independent experiments
performed in triplicate. p < 0.01 for *S1P versus control or S1P + Dox versus
Dox, and #S1P or S1P + Dox versus S1P + mAb or S1P + Dox + mAb. All data
are represented as the mean 6 SEM.with respect to the control (taken as 1), in at least three independent experiments performed in duplicate. Matrigel plugs containing saline or 5 mM S1P were
quantified for EC invasion after 10 days with Masson Trichrome (D). Selected animals received the anti-S1P mAb (25 mg/kg, every 48 hr). In the B16-F10 allograft
model, mice bearing murine melanoma tumors were treated with saline, 25 mg/kg of the nonspecific mAb, and 25 mg/kg of the anti-S1P mAb (E). Data rep-
resent tumor volumes and tumor weights (inset) from nine mice per group. Animals treated with the anti-S1P mAb showed 57% and 53% reductions in tumor
volumes and weights, respectively. F and G show representative images and graphic quantification of tumors stained with isolectin or CD31, respectively.
White arrows indicate tumor margins. p < 0.01 for ADox/Tax versus saline, *S1P + Dox/Tax versus Dox/Tax, and #S1P + Dox/Tax versus S1P + Dox/Tax + mAb;
or p < 0.05 for 6anti-S1P mAb versus saline/nonspecific mAb and for *anti-S1P mAb versus control. All data are represented as the mean 6 SEM.233
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The molecular sponge concept proposed here
envisions that the antibody will neutralize S1P
and prevent its cancer growth-promoting ef-
fects. We also propose that the resulting
decrease in the effective extracellular concen-
tration of the protective S1P would alter the
rheostat in cancer cells in favor of ceramide
and sphingosine, two well-known proapoptotic
signaling molecules that can be activated in
cancer cells by radiation and chemotherapeu-
tic agents. Thus, we propose that a S1P molecu-
lar sponge would have multiple mechanisms of
antitumor action when used as an adjunct to
standard chemotherapy or radiation therapy.(0.001–1.0 mg/ml) (Figure S5), while the nonspecific antibody
completely lacked the ability to reduce S1P-protective affects
against doxorubicin-induced cell death (Figure S6).
The ability of the anti-S1P mAb to mitigate the effects of S1P
in these in vitro assays suggests that (1) the mAb can effectively
neutralize the direct protumorigenic effects of S1P on tumor
cells; and (2) the affinity of the mAb for S1P was higher than
that of the S1P receptors expressed by the tumor cells. In addi-
tion, the lack of responsiveness of the B16-F10 mouse mela-
noma cells to the direct actions of S1P supports the data in
Figure 5F and demonstrates that S1P has a profound angio-
genic effect on tumor progression.
Discussion
In this study, we used a highly specific monoclonal antibody
against S1P as a molecular sponge to selectively absorb and
neutralize this bioactive lipid mediator in in vitro and in vivo
models designed to evaluate potential angiogenic and tumori-
genic effects of S1P. The anti-S1PmAbblocked both S1P’s pro-
survival and angiogenic actions and has proved to be a useful
tool in evaluating the actions of S1P. The ability of the anti-
S1P mAb to significantly retard the progression, and in some
cases eliminate established tumors of human and mouse ori-
gins, was consistent with the profound proangiogenic effects
of S1P. Taken together, these data imply that the anti-S1P
mAb warrants evaluation in human clinical trials.
The studies presented here suggest that a principal mech-
anism of the anti-S1P mAb in blocking tumor progression is
through the neutralization of the proangiogenic effects of the234blood-borne lipid mediator S1P. The proangiogenic effects of
S1Pwere demonstrated in an in vivo allograft tumormodel using
the B16-F10 cells, in vivo with the Matrigel plug assay as well as
in in vitro studies using HUVECs. Unexpectedly, the anti-S1P
mAb also inhibited the release of proangiogenic cytokines
in vitro and in vivo, while also potently blocking the function of
VEGF and bFGF in vivo. The effects of anti-S1P mAb on VEGF
and bFGF suggest either that S1P is permissive for the angio-
genic effects of VEGF and bFGF or that S1P acts as the ultimate
downstream mediator of VEGF and bFGF. A central and obliga-
tory role for S1P on VEGF action, as suggested by our data, is in
agreement with published results showing that VEGF receptors
are transactivated by S1P (Igarashi et al., 2003). Regardless,
these data confirm and validate the important role of S1P during
vascularization and further suggest that the anti-S1P mAb may
exhibit a wide spectrum of activity considering the complexity
of the tumor environment.
In addition to the antiangiogenic effect of the anti-S1P mAb,
the antibody inhibited tumor cell proliferation, invasion, and
survival against standard chemotherapeutics. The reduction
of tumor vasculature along with the neutralization of the prosur-
vival effects of S1P on tumor cells suggests that this antibody
could be used as a clinical adjunct to conventional chemother-
apy by sensitizing tumor cells to anticancer agents and possi-
bly reducing the effective dose of cytotoxic chemotherapeutic
agents.
Themechanism for the antitumorigenic effects of the anti-S1P
mAb is simple neutralization of S1P by selective absorption. In
addition to the endogenous plasma S1P, new sources of S1P
in a tumor-bearingmouse could include S1P produced by tumorCANCER CELL MARCH 2006
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SPHK oncogene (French et al., 2003; Johnson et al., 2005) or
from stromal and inflammatory cells or other components at-
tracted to the tumor. Regardless of the S1P source, the efficacy
of anti-S1P mAb action demonstrates the importance of S1P in
tumor aggressiveness and also validates the anti-S1P mAb as
a potential therapeutic agent. Figure 7 shows how this strategy
may be useful in cancer treatment and compares S1P as a can-
cer target to other key components of the sphingolipid signaling
cascade. This molecular sponge concept is similar to the mech-
anism of action of Avastin, a humanized mAb directed against
the proangiogenic growth factor VEGF (Ferrara, 2004). In con-
trast to the anti-VEGF strategy of neutralizing tumorigenic
growth factors, most anticancer therapeutic antibodies are
directed against tumor-selective antigens expressed on the
surfaces of transformed cells. These therapeutic antibodies
are often conjugated to radionuclides or other toxic payloads
and deliver the materials to tumors by molecular targeting.
The efficacy of this treatment depends, in part, on the accessi-
bility of the antibodies to the tumor cells. As is the case for
Avastin, the anti-S1P mAb used here may not suffer from this
limitation in that the target, S1P, is circulating in the same com-
partment (i.e., blood) as is the antibody. Further, S1P is a small
molecule (MW = 379 Da) and a lipid target that is thought to
freely cross cell and compartment boundaries more easily
than protein targets like VEGF. An additional potential advan-
tage of an anti-S1PmAb is that the target is not species specific,
as is the case with cancer targets of protein origin. S1P has the
same chemical composition not only across species, but also
across phyla, and it is not susceptible to mutation as a means
of escaping the therapeutic.
An additional potential benefit of reducing the effective ex-
tracellular S1P concentration with the anti-S1P mAb may be
in altering the sphingolipid signaling rheostat in favor of CER
and SPH as it neutralizes S1P (Figure 7). CER and SPH are
well-known proapoptotic intracellular signaling molecules that
can be activated in cancer cells by radiation and chemothera-
peutic agents (Gouaze et al., 2001; Kolesnick and Fuks, 2003)
and can promote apoptosis in tumor cells (Kurinna et al.,
2004), in contrast to S1P, which largely serves a protective
function for cancer cells. Altering the rheostat in favor of
CER would augment the anticipated ability of the anti-S1P
mAb to serve as an adjunct to standard chemotherapy or radi-
ation therapy.
Taken together, the selective absorption of S1P by a neutraliz-
ing antibody could represent a promising approach to cancer
therapy. This approach may have advantages over other targets
in the sphingolipid signaling cascade, such as targeting key en-
zymes of the S1P biosynthetic pathway responsible for S1P pro-
duction (Figure 7). The pleiotropic effects of S1P in promoting
tumor growth, metastasis, and angiogenesis make S1P a robust
target for anticancer therapy because S1P has several mecha-
nisms of action. Thus, the anti-S1P mAb could sensitize cancer
cells to anticancer agents while exerting antiproliferative, anti-
angiogenic, and antimetastatic effects. The molecular sponge
approach for neutralizing S1P, coupled to the finding that anti-
bodies have favorable pharmacokinetic features and high ther-
apeutic indices, suggest that an anti-S1P antibody may provide
therapeutic benefits in treating a broad range of cancers. How-
ever, clinical trials with a humanized version of the mouse anti-
body will be needed to confirm this contention.CANCER CELL MARCH 2006Experimental procedures
Materials
S1P, LPA, SPH, and other lipids were obtained from Avanti Polar Lipids or
from Calbiochem. S1P, LPA, and SPH were complexed with fatty acid-free
BSA (1 mg/ml in PBS) as a solvent-free carrier. Dulbecco’s modified Eagle’s
medium (DMEM) and fetal bovine serum (FBS) were purchased from Invitro-
gen. EMB-2 medium and Bullet Kit were purchased from Cambrex. GFR and
Matrigel basement membrane matrix were purchased from BD BioSciences.
Anti-mouse CD31 primary antibody was obtained fromChemicon. Horserad-
ish peroxidase (HRP)-conjugated goat anti-mouse secondary antibody and
the rhodamine red-X-conjugated rabbit anti-mouse CD31 was purchased
from Jackson Immunoresearch. [3H]-thymidine was from Amersham Biosci-
ence. Recombinant murine VEGF was obtained from PeproTech. Fluores-
cein Griffonia (Bandeiraea) Simplicifolia Lectin I, Isolectin B-4 was obtained
from Vector Laboratories. High-sensitivity ELISA-based kits for cytokine de-
terminations were purchased from R&D Systems. All other reagents were
purchased from Sigma. An IgG1 isotype-matched mouse mAb directed
against a plant antigen was obtained from Strategic BioSolutions and used
as a control antibody.
Cell culture
Human lung carcinoma (A549), human breast adenocarcinoma (MCF-7), hu-
man colorectal adenocarcinoma (HT-29), and the mouse melanoma (B16-
F10) cell lines were obtained from American Type Culture Collections.
SKOV3, MDA MB-231, and MDA MB-468 cells were obtained from the
M.D. Anderson Cancer Center (Houston, TX). Cells were subcultured twice
a week as per care instructions and did not exceed passage 10. HUVECs
were obtained from Cambrex, maintained in EGM-2 media supplemented
with EGM-2 Bullet Kit, and used between passages 3 and 8. Tumor cells
were maintained in DMEM supplemented with 10% FBS, unless otherwise
stated, at 37ºC in a humidified 5% CO2 atmosphere.
Animals
Four- to six-week-old female C57BL/6 and athymic nude (Ncr Nu/Nu) mice
were obtained from Harland. All experiments were performed in accordance
with NIH guidelines for the humane use of animals. All protocols involving the
use of animals were approved by the IACUC committees at M.D. Anderson
Cancer Center and San Diego State University (SDSU; protocol numbers:
04-04-010S, 04-08-020S) and conformed to all regulatory standards (NIH as-
surance #A3728-01 and USDA Veterinary Permit #7793).
Production of the anti-S1P mAb
For immunization, S1P was conjugated to KLH. Swiss Webster mice were
immunized four times over a 2month period with 50 mg immunogen per injec-
tion. Serum samples were collected 2 weeks after the second, third, and
fourth immunizations and were screened by ELISA for the presence of anti-
S1P antibodies. Spleens from animals that displayed high titers of the anti-
body were subsequently used to generate hybridomas using standard fusion
procedures. The resulting hybridomas were grown to confluency, after which
cell supernatants were collected for ELISA analysis to identify positive hy-
bridoma clones. For ascites production, SCID mice were injected i.p. with
the positive clonal cells. Monoclonal antibodies were purified by Protein A
and were >95% pure by HPLC. Endotoxin levels were <3 EU/mg. The anti-
body was prepared in 20 mM sodium phosphate with 150 mM sodium chlo-
ride (pH 7.2) and stored at 280ºC.
ELISA
Ninety-six-well high binding ELISA plates (Costar) were coated overnight
with S1P diluted in PBS (137 mM NaCl, 2.68 mM KCl, 10.1 mM Na2HPO4,
1.76 mM KH2PO4; pH 7.4) containing 1% BSA at 4ºC. Plates were washed
with PBS and blocked with PBS/BSA for 1 hr. For the primary incubation,
0.1 mg/ml anti-S1P mAb and designated amounts of S1P, LPA, phosphatidyl
serine (PS), PE, CER, C1P, SPH, dihydrosphingosine (DH-SPH), sphingo-
myelin (SM), SPC, and dihydrosphingosine-1-phosphate (DH-S1P) were
added to wells of the ELISA plates. Plates were washed and incubated
with 100 ml per well of 0.1 mg/ml HRP-conjugated goat anti-mouse secondary
for 1 hr at room temperature. Plates were then exposed to tetramethylbenzi-
dine for 1–10 min. The detection reaction was stopped by the addition of an235
A R T I C L Eequal volume of 1 M H2SO4. Optical density of the samples was determined
by measurement at 450 nm using a Thermo Multiskan EX.
Pharmacokinetic experiments
Eight-week-old C57/Bl mice were dosed with 25 mg/kg of the anti-S1P mAb
i.v. and bled at designated time points. A competitive ELISA using a biotin-
labeled anti-S1P mAb was used to determine the concentration of antibody
remaining in the mouse blood between 20 and 120 min after the bolus dose.
A standard two compartmentmodel calculation inWinNonlin was used to de-
termine the t1/2 of the antibody. The experiment was repeated three times
with three animals per group each time.
Toxicology study
Eight- to twenty-week-old female and male C57/Bl mice were treated with 1,
3, 10, 30, or 50mg/kg of the anti-S1P mAb or vehicle (sterile saline) for 7 con-
secutive days by tail vein injection. Solutions for injection were made daily.
Twenty-four hours after the final treatment, the mice were sacrificed, blood
was collected by venous puncture, and organs were harvested. Whole blood
and serum were sent to a veterinary testing laboratory (IDEXX Laboratories)
for standard CBC and biochemical panel analysis. Tissue samples were
stored in 10% formalin and shipped to a board-certified pathologist (Com-
parative Biosciences) for evaluation.
Cell proliferation assays
Cells were seeded onto 12-well tissue culture plates (13 105 cells per well) in
DMEM containing 10% FBS. During treatment, cells were incubated in 10%
FBSDMEM, containing either 1mg/ml BSA in PBS as a vehicle control or var-
ious concentrations of S1P. The cells were incubated with or without anti-
S1P mAb (1 mg/ml). For S1P plus antibody treatments, S1P was incubated
with the anti-S1P mAb (1 mg/ml) in the media for 1 hr prior to addition to
the cells. After 24 hr, cells were labeled with 1 mCi/ml [3H]-thymidine and in-
cubated for an additional 6 hr at 37ºC. Labeled cells were fixed with ice-cold
10% TCA for 30 min at 4ºC and then washed three times with ice-cold 10%
TCA to removed unincorporated [3H]-thymidine. The cells were then lysed in
1 N NaOH, and the radioactivity was counted.
Chemoinvasion assay
Cells (5 3 104 cells per well) were suspended in DMEM with 0.1% FBS and
added to the top chamber of a BD BioCoat TM Invasion Systems (BD Biosci-
ences). FBS media (10%) were used as a chemoattractant in the bottom
chamber. The anti-S1P mAb (0.01, 0.1, or 1 mg/ml), and various concentra-
tions of S1P (100 nM, 500 nM, 1 mM, and 2 mM) were preincubated for 1 hr
and then added to cells in the top chamber. Tumor cells were allowed to mi-
grate for 22 hr, at 37ºC.
EC migration assays were performed using modified Boyden chambers
(Corning Constar) coated with Matrigel matrix (500 mg/ml). Serum-deprived
HUVECs (5 3 104 cells per well) were resuspended in minimum media (2%
FBS) and added to the top chambers. S1P (100 nM) with or without the
anti-S1P mAb (1 mg/ml) was added to the bottom chambers, and HUVECs
were allowed to migrate for 6 hr at 37ºC. After treatment, migrating cells
were stained with HEMA 3 stain set (Fisher Scientific) as per the manufac-
turer’s protocol. Five fields per filter were counted at 403 (Nikon Labo-
phot-2). Data are expressed as the fold increases of cell invasion with respect
to the nontreated control cells for at least four independent experiments per-
formed in duplicate.
Cell death assays
Cells (2–2.5 3 105 cells per well) were seeded into 6-well plates and allowed
to grow to 80% confluence prior to treatment. The cells were then treated
with and without 0.5–1 mM doxorubicin (Andriamycin) hydrochloride, 50–
500 nM paclitaxel (Taxol), 0.1–1 mM S1P, and 1 mg/ml of the anti-S1P mAb,
in 10% FBS DMEM for 48 hr. Treated media were replaced with fresh media
after 24 hr. After 48 hr, the cells were washed twice with PBS and lysed in
85 ml of caspase assay buffer (0.5 M HEPES [pH 7.4], 10% Chaps, 0.5 M
EDTA). Samples were then centrifuged at 14,000 rpm in an Eppendorf Cen-
trifuge 5417C for 5 min to discard cellular debris. Caspase-3 activity in the
supernatant was measured by caspase-3 assay kit (A.G. Scientific) accord-
ing to the manufacturer’s protocol and was standardized by protein determi-
nation with a BCA detection kit (Pierce). Caspase-3 activity is expressed as
the fold increase in fluorescence signal with respect to nontreated cells. For236the MCF-7 cells that do not express caspase-3, Hoechst/propidium iodide
staining was used to evaluate cell death. At least three independent experi-
ments were performed with triplicate runs of each condition.
EC tube-like formation assay
The formation of vascular-like structures was assessed on GFRMatrigel ma-
trix. Tissue culture plates were coated with 300 ml of GFRMatrigel diluted 1:2
with serum-free media (0% FBS, 1 mg/ml of BSA). Matrigel was allowed
to polymerize for 2 hr at 37ºC. Serum-deprived HUVECs (5 3 105 cells
per well) were suspended in serum-free media, seeded onto the polymerized
matrix, treated with 1 mM of S1P with or without the anti-S1P mAb (1 mg/ml),
and incubated at 37ºC for 6 hr. Tubular networks were visualized after 6 hr at
103 (Olympus IX-70) and visualized using PhotoShop 6.0.
Cytokine release assay
Cells were starved of serum and treated with the indicated concentrations of
S1P and/or the anti-S1P mAb for 22 hr. Cell-conditioned media were col-
lected and assessed for IL-6, IL-8, and VEGF by ELISA as suggested by
the manufacturer (R&D Systems). Data are presented as the fold increase
with respect to nontreated cells.
In vivo matrigel plug assay
Angiogenesis in vivo was performed using the Matrigel plug assay (Staton
et al., 2004). Anesthetized C56BL/6 mice were injected in the left flank with
500 ml of ice-cold GFR Matrigel. The GFR Matrigel was injected either alone
(nontreated group) or with 0.5–1 mg/ml bFGF, 10 mg/ml VEGF, or 5 mM S1P.
Each treatment group consisted of a minimum of three mice. Subsets of an-
imals were treatedwith the anti-S1PmAb (either 1 or 25mg/kg). Dosing of the
anti-S1P mAb was initiated 1 day prior to the implantation of Matrigel, and
each dose was administrated i.p. every 48 hr for the duration of the experi-
ments. After 10 days, the mice were heparinized (12.8 mg/ml) and then in-
jected i.v. with 200 ml of Fluorescein Griffonia (Bandeiraea) Simplicifolia I,
Isolectin B-4 (0.5 mg/ml) 15 min prior to sacrifice. The plugs were excised,
immediately embedded in OCT, frozen in isopentane/dry ice, sectioned
(80 mm), and then mounted with coverslips using antifade mounting medium
(VectaShield, Vector). Microvascular density was visualized using a Leica
TCS SP2 inverted confocal microscope. Digital images were acquired using
Leica Analysis Software, and the fluorescence was then quantified by Photo-
Shop 6.0 program and expressed as capillary density (pixel2) by ImageJ. Se-
lected sections (10 mm) from each treatment were also analyzed by Masson
Trichrome staining. ECs infiltrating (and/or proliferating) into the plugs were
counted at 1003 resolution in five fields from nine sections per plug.
Xenograft and allograft mouse models
Nude mice were implanted s.c. with 2.53 106 A549 cells on the left flank, or-
thotopically into the mammary fat pads with 1 3 107 MDA MB-231 or MDA
MB-468 cells or i.p. with 1 3 107 SKOV3 cells. Alternatively, 5 3 105 B16-
F10 cells were implanted s.c. into the flanks of C57/Bl6 mice. Tumors were
allowed to establish (75–200 or 700–800 mm3), and then the mice were ran-
domly divided into treatment groups (5 to 20 mice per group). Treatment
groups were as follows: vehicle (saline) control, 20 mg/kg isotype-matched
nonspecific mAb, 10–20 mg/kg anti-S1P mAb, and 10 mg/kg Taxol diluted
to 2 mg/ml with saline. Taxol was administered once per week while all other
treatments (antibodies or saline) were administered every 3 days. Measure-
ments of tumor volume were made using calipers every 3 days by two
blinded individuals and averaged. The study was terminated when the first
mouse reached a maximum average volume as per IACUC standards. At
the end of the study, final volumes were taken, and tumors were collected
for histology. Histological features and microcapillary density were assessed
by H&E, FITC-isolectinB4, andCD31 staining of vessels, respectively. For the
FICT-isolectinB4 staining in the B16-F10 model, tumors from saline- and
anti-S1P mAb-treated animals were sectioned (80 mm), and four sections
from different regions of each tumor were selected and assessed by isolectin
staining by confocal microscopy (103). For the CD31 staining in the B16-F10,
SKOV3, and A549 models, tumor sections (10 mm) were blocked overnight
and stainedwith rat anti-mouse CD31 (1:50 dilution) and then with rhodamine
red-X-conjugated rabbit anti-rat antibody (1:500 dilution), for 1 hr at room
temperature each. Selected sections of each tumor were assessed by the
rhodamine-X staining (403). Each section was expressed as sum of capillary
density (pixel2) in six random fields (two in the tumor center and four in theCANCER CELL MARCH 2006
A R T I C L Eperiphery), and values of the sections derived from each tumor were aver-
aged. Final tumor vasculature score was expressed as the average of capil-
lary vessel density present in the two treatment groups (n = 3/4 animals per
group). Studies were completely blinded to all those collecting and analyzing
the data until all data were finalized.
Magnetic resonance imaging
Animals anesthetized with inhaled isoflurane were imaged with a 4.7 T small
animal MR (Bruker) axially (TE 60ms, TR 5700ms, 4 Nex, field of view 3.5 cm,
slice thickness 1 mmwith 0.3 mm skip, matrix 2563 256, in plane resolution
150 mm) and sagittally (TE 80 ms, TR 4500 ms, 4 Nex, field of view 3.5 cm,
slice thickness 1 mmwith 0.3 mm skip, matrix 2563 256, in plane resolution
230 mm) using a T2-weighted fast spin echo (FSE) sequence.
Statistical analysis
Data are presented as means 6 SEM except for those shown in Figure 1C.
Statistical significance of the differences between experimental groups
was calculated by one-way ANOVA and an unpaired Student’s t test using
Graphpad software.
Supplemental data
The Supplemental Data include six supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/3/
225/DC1/.
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